Switch theme
Sign up to access all valuation multiples
Shanghai RAAS Blood Products Co Ltd is a blood products manufacturer in China that has a high comprehensive utilization of plasma raw materials and different specifications. It is engaged in the research, development, and manufacture of blood products and plasma-derived medical products. The main products are human albumin, intravenous human immunoglobulin, coagulation factor products, etc.
1988
272
LTM Revenue $1.2B
LTM EBITDA $359M
$5.9B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Shanghai RAAS has a last 12-month revenue (LTM) of $1.2B and a last 12-month EBITDA of $359M.
In the most recent fiscal year, Shanghai RAAS achieved revenue of $1.1B and an EBITDA of $395M.
Shanghai RAAS expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Shanghai RAAS valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $1.2B | XXX | $1.1B | XXX | XXX | XXX |
| Gross Profit | $475M | XXX | $463M | XXX | XXX | XXX |
| Gross Margin | 40% | XXX | 41% | XXX | XXX | XXX |
| EBITDA | $359M | XXX | $395M | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 35% | XXX | XXX | XXX |
| EBIT | $329M | XXX | $306M | XXX | XXX | XXX |
| EBIT Margin | 28% | XXX | 27% | XXX | XXX | XXX |
| Net Profit | $322M | XXX | $306M | XXX | XXX | XXX |
| Net Margin | 27% | XXX | 27% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of July 18, 2025, Shanghai RAAS's stock price is CNY 7 (or $1).
Shanghai RAAS has current market cap of CNY 46.5B (or $6.5B), and EV of CNY 42.5B (or $5.9B).
See Shanghai RAAS trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $5.9B | $6.5B | XXX | XXX | XXX | XXX | $0.05 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of July 18, 2025, Shanghai RAAS has market cap of $6.5B and EV of $5.9B.
Shanghai RAAS's trades at 5.2x EV/Revenue multiple, and 15.0x EV/EBITDA.
Equity research analysts estimate Shanghai RAAS's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Shanghai RAAS has a P/E ratio of 20.1x.
See valuation multiples for Shanghai RAAS and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.5B | XXX | $6.5B | XXX | XXX | XXX |
| EV (current) | $5.9B | XXX | $5.9B | XXX | XXX | XXX |
| EV/Revenue | 5.0x | XXX | 5.2x | XXX | XXX | XXX |
| EV/EBITDA | 16.5x | XXX | 15.0x | XXX | XXX | XXX |
| EV/EBIT | 18.0x | XXX | 19.4x | XXX | XXX | XXX |
| EV/Gross Profit | 12.5x | XXX | n/a | XXX | XXX | XXX |
| P/E | 20.1x | XXX | 21.2x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -47.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialShanghai RAAS's last 12 month revenue growth is 5%
Shanghai RAAS's revenue per employee in the last FY averaged $4.2M, while opex per employee averaged $0.6M for the same period.
Shanghai RAAS's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Shanghai RAAS's rule of X is 43% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Shanghai RAAS and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 5% | XXX | 5% | XXX | XXX | XXX |
| EBITDA Margin | 31% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Growth | 12% | XXX | 8% | XXX | XXX | XXX |
| Rule of 40 | 35% | XXX | 39% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 43% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $4.2M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.6M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 4% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 3% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 14% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Shanghai RAAS acquired XXX companies to date.
Last acquisition by Shanghai RAAS was XXXXXXXX, XXXXX XXXXX XXXXXX . Shanghai RAAS acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Shanghai RAAS founded? | Shanghai RAAS was founded in 1988. |
| Where is Shanghai RAAS headquartered? | Shanghai RAAS is headquartered in China. |
| How many employees does Shanghai RAAS have? | As of today, Shanghai RAAS has 272 employees. |
| Is Shanghai RAAS publicy listed? | Yes, Shanghai RAAS is a public company listed on SHE. |
| What is the stock symbol of Shanghai RAAS? | Shanghai RAAS trades under 002252 ticker. |
| When did Shanghai RAAS go public? | Shanghai RAAS went public in 2008. |
| Who are competitors of Shanghai RAAS? | Similar companies to Shanghai RAAS include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Shanghai RAAS? | Shanghai RAAS's current market cap is $6.5B |
| What is the current revenue of Shanghai RAAS? | Shanghai RAAS's last 12 months revenue is $1.2B. |
| What is the current revenue growth of Shanghai RAAS? | Shanghai RAAS revenue growth (NTM/LTM) is 5%. |
| What is the current EV/Revenue multiple of Shanghai RAAS? | Current revenue multiple of Shanghai RAAS is 5.0x. |
| Is Shanghai RAAS profitable? | Yes, Shanghai RAAS is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Shanghai RAAS? | Shanghai RAAS's last 12 months EBITDA is $359M. |
| What is Shanghai RAAS's EBITDA margin? | Shanghai RAAS's last 12 months EBITDA margin is 31%. |
| What is the current EV/EBITDA multiple of Shanghai RAAS? | Current EBITDA multiple of Shanghai RAAS is 16.5x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
